The BioPharm Brief: Smarter Immunotherapy, Stronger Responses, Longer Survival

Jun 01, 08:38 PM
Headliner
Share
Subscribe

New data in lung cancer and solid tumors highlight the growing impact of next-generation immunotherapies, including bispecific antibodies and TCR-based therapies, as developers report encouraging efficacy across difficult-to-treat patient populations.

Share
Subscribe
Next
The BioPharm Brief: Gene Therapy Reform, Cancer Trial Endpoints, and a $1.2B Rare Disease Deal
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief